Immunic, inc. to participate in industry and investor conferences in march

New york, march 2, 2021 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced management's participation in the...

IMUX Ratings Summary

IMUX Quant Ranking